Day 1 - Prostate Cancer

The most common adverse reactions with XTANDI are asthenia/fatigue, hot flush, hypertension, fractures, and fall. Other important adverse reactions include ischemic heart disease and seizure.

In the ARCHES trial in patients with mHSPC Grade ≥ 3 AEs occurred in 24.3% of patients treated with Xtandi plus ADT, compared with 25.6% for patients treated with placebo plus ADT. The most common ≥ Grade 3 AE in patients treated with XTANDI plus ADT were Hypertension (3.3%) Asthenia (1%), Back Pain (0.9%) Fatigue (0.9%), Hot flashes (0.3%), Arthralgia (0.3%) and Increased weight (0.3%).

Please consult the Summary of Product Characteristics for more information on adverse events and safety details.

Expert presentation covering recent data in the high-risk BCR nmHSPC setting and discussion around its implication for patients. The Faculty covered the data in detail, discussed the treatment options available to patients with high-risk BCR nmHSPC and highlighted the role of imaging and its impact on management in patients with high-risk BCR.

Fight club debate considered the following point of view: ‘Modern imaging should be used to assess progression in all patients with advanced prostate cancer’.

Workshop sessions took place in five breakout rooms, during which the Faculty presented complex patient case studies. 
Each case study covered a different patient case and discussed optimal treatment approaches, based on clinical data and expert experience. Attendees were encouraged to contribute and share insights within the breakout groups.

Presentation from a multidisciplinary panel which covered the key considerations for managing QoL in patients with mHSPC.
The expert Faculty summarised recent QoL data updates, discussed these in the context of a relevant patient case study and clarified how data can be differentiated between being statistically significant and clinically meaningful.

Discussion around the key topics from APCCC 2024 and how these can be used to provide treatment and management recommendations in the field of advanced PCa.

Summary of the key points covered during Day 1 of the meeting.

Grade ≥3 TRAEs occurred in 55.9% of those treated with PADCEV + pembrolizumab and 69.5% with platinum-based chemotherapy. The most common Grade ≥3 TRAEs of special interest for PADCEV + pembrolizumab included skin reactions (15.5%), peripheral neuropathy (6.8%) and hyperglycaemia (6.1%).

Overview of how the treatment landscape and international guidelines for advanced mUC have evolved over recent years, the 
key therapy options available for patients with unresectable LA/mUC, and the remaining unmet needs for patients in this therapeutic space.

Discussion of the advancements in recent years within the ≥2L LA/mUC space and deliberation on the impacts these have had for patients with LA/mUC, evidenced through RWE.

Deep dive into the pivotal Phase III data for the recent standard of care for patients with 1L unresectable LA/mUC.

Overview of overall management techniques and warning signs for key adverse events of special interest with treatments. Discussion with all Faculty to delve into hot topics, such as management of peripheral neuropathy with insights from Dr Ippen, a neurologist and management of skin toxicities with insights from Dr Carmona Rocha, a dermatologist.

Workshop sessions covering skin toxicity, peripheral neuropathy, transaminitis, diarrhoea and hyperglycaemia took place in four breakout rooms, where each room was presented three patient case studies in turn and the group openly discussed approaches towards the management of the patient’s adverse events.

Faculty discussion considering the following point of view: ‘Should all platinum-eligible patients with unresectable LA/mUC receive 1L treatment with the recent standard of care?’’